A drug for erectile dysfunction is created on the basis of the venom of the Brazilian spider
A peptide that mimics the venom of the Brazilian wandering spider helps maintain erections. The study is reported by the press service of the Federal University of Minas Gerais in Brazil.Researchers from the Federal University of Minas Gerais in Brazil have synthesized an artificial molecule to combat erectile dysfunction. The development is based on the properties of toxins from venomous Brazilian wandering spiders (Phoneutria nigriventer). The first phase of clinical trials confirmed the safety of the drug.
Phoneutria nigriventer is an extremely venomous spider of the family Ctenidae found in South American countries. The venom of this arthropod causes involuntary, painful and prolonged erection, priapism, especially in young men. Researchers for 20 years studied various properties of the venom to determine the molecules that cause such a reaction in the human body.
Scientists isolated the erection-affecting peptide from the venom and synthesized its artificial but safe copy BZ371A in the lab. This molecule is characterized by a smaller size and does not have a toxic effect on the body. In tests on isolated tissues and animals, the scientists confirmed that exposure to BZ371A causes a sustained erection.
Researchers have developed a topical application gel based on BZ371A. When applied to the groin area. Like the toxin in spider venom, this peptide releases nitric oxide, a common and major neurotransmitter regulating the erection process. Once the gel is applied to the body, there is a dramatic increase in the release of nitric oxide, which leads to the dilation of the cavernous bodies of the penis and the restoration of erection.
Together with the Brazilian pharmacological company Biozeus, the researchers conducted the first phase of preclinical trials. The analysis showed that the drug does not cause significant side effects and is safe for humans. In a study on men and women, scientists showed that topical application of BZ371A leads to vasodilation independent of other stimuli. In men, this has an effect on penile erections.
Unlike traditional erectile dysfunction drugs (such as Viagra), topical application of BZ371A reduces the risk of adverse cardiovascular effects, the researchers note. Biozeus is currently preparing a Phase II clinical trial, during which a double-blind study will evaluate the efficacy of the drug in men with erectile dysfunction.